To the Editor:
In the United States over 180 million prescriptions for antibiotics are filled each year; they represent the most commonly prescribed drugs. 1 T h e vast majority of studies evaluating the appropriateness of antibiotic usage have been conducted on hospital inpatients, but few in an outpatient setting. 1 3 This lack of surveillance leads to unnecessary therapy, poor drug choice, misguided prophylaxis, and inordinate cost to the health care system.
We conducted a study on antibiotic usage in our Community Hospital Emergency Room. The records of our Emergency Department were retrospectively reviewed on two separate, random occasions. All cases in which the diagnosis was an infectious disease or an antibiotic was prescribed are included in the study.
A baseline audit of 200 consecutive charts were reviewed from August [1] [2] [3] 1985 . Forty-four p a t i e n t s (22%) received antibiotics. Prophylactic antibiotics were prescribed to 14 patients (32%) (superficial wounds of hands and feet treated with penicillin or its derivative, or an oral cephalosporin). Inappropriate antibiotics were prescribed to five patients (11%) (viral syndrome [3 cases ], uninfected herpes zoster, tetracycline to treat Group A beta hemolytic tonsillo-pharyngitis). Appropriate antibiotics were prescribed to the remaining 25 cases (57%) (bronchitis with penicillin or its derivative, or an oral cephalosporin; tonsillo-pharyngitis with penicillin or its derivative; otitis media with penicillin or its derivative; urethritis and pelvic inflammatory disease with doxycycline; urinary tract infection with trimethoprim-sulfamethoxazole or penicillin derivatives; a n d diverticulitis with penicillin derivatives). Of these 25 cases, it was necessary to culture 20 patients (46%) (tonsillopharyngitis, urethritis, urinary tract infection, and pelvic inflammatory disease). Actually only one patient was cultured. A Quality Assurance Program was then formulated in an attempt to modify physician prescribing patterns and increase appropriate culturing. A novel antibiotic prescription form devised by a Massachusetts group (Durbin, et al) was modified by us into a stamp. 4 Obligatory use of this antibiotic stamp required physicians to categorize antibiotic use as either prophylactic, empirical, or therapeutic. I n -s e r v i c e e d u c a t i o n a l sessions stressed that in each clinical situation t h e o p t i m a l use of an antibiotic d e p e n d s u p o n c o n s i d e r a t i o n of efficacy, safety, acceptability, cost, and culturing when appropriate prior to use.
A follow-up audit of 260 consecutive charts was conducted six months later, March 3-5, 1986 . Fifty-two patients (20%) received antibiotics. Prophylactic antibiotics were prescribed to 10 patients (19%) (superficial wounds of hands and feet with penicillin or its derivative, or with an oral cephalosporin). I n a p p r o p r i a t e antibiotics were prescribed to three patients (6%) (for viral syndrome). Appropriate antibiotics were prescribed to the remaining 39 patients (75%) (bronchitis with penicillin or its derivative tetracycline or erythromycin; tonsillopharyngitis with penicillin or its derivative, or erythromycin; otitis media with penicillin or its derivative or an oral cephalosporin; urethritis and pelvic inflammatory disease with penicillin or its derivative, erythromycin, or an oral cephalosporin; urinary tract infection with trimethoprim-sulfamethoxazole or penicillin deriva* tives; and lobar p n e u m o n i a with erythromycin). Of these 39 cases, it was necessary to culture 21 patients (40%) (tonsillo-pharyngitis, urethritis, urinary tract infection, pelvic inflammatory disease). This time eight patients (38%) were cultured. There was 100% compliance with the antibiotic stamp.
Comparing the two audits, there was an almost 50% decrease in inappropriate antibiotic use with a con comitant improvement in appropriate continued on page 184
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Letters to the Editor To realize the benefits of the disposable inner cannula, the health care professional simply needs to follow these four important steps:
Step 1-Remove the used inner cannula, employing aseptic procedures, by firmly pinching the clamps of the snap-lock connector and gently pulling back from the tracheostomy tube. The professional should note the size of the tube for correct DIC replacement.
Step 2-Important! After determining that the inner cannula is indeed a disposable type (and not a reusable inner cannula with a twist lock), discard the DIC in an appropriate disposal container. Remember, do not clean, resterilize, or reuse the DIC.
Step 3-Remove the correct size DIC from its sterile container by the pinch clamps of the snap-lock connector using aseptic technique.
Step 4-Still using aseptic technique, insert the new DIC, securely snapping both sides of the connector, and proceed with hospital-prescribed trach care. The sterile tray from the DIC makes a convenient basin for stoma care.
So, take a big step in reducing the risk of contamination and infection-by throwing away the used disposable inner cannula. continued from page 182 usage. Furthermore, the incidence of appropriate culturing increased from 5% to 38%, a better than sevenfold increase.
We conclude that through an easy and inexpensive Quality Assurance Program comprised of in-service educational sessions, simple audit, and the use of a novel antibiotic stamp, the physician's consciousness can be raised to apply sound principles in the usage of antibiotics and culture. The result is an increase in appropriate antibiotic use and prior culturing when needed. The benefit is to the patient through an augmented quality of care and to the health care system through elimination of unnecessary and excessive cost.
Corrections in November Brief Report
The Editor apologizes for the following errors which occurred in the Brief Report "Influence of Country of Origin on Prevalence of Hepatitis B Markers Among Employees in a Small Suburban Hospital" by Frank W. Kiel, MD, November 1986, pp. 554-557. In addition, the Editor regrets any inconvenience these errors may have caused the author or the reader.
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AS PRINTED
Foreign-born participants accounted for 68% of the employee population. RECOMBIVAX-HB will not prevent hepatitis caused by other agents, such as hepatitis A virus, non-A, non-B hepatitis viruses, or other viruses known to infect the liver.
Vaccination is recommended in persons of all ages who are or will be at increased risk of infection with hepatitis B virus. In areas with high prevalence of infection, most of the population are at risk of acquiring hepatitis B infection at a young age. Therefore, vaccination should be targeted to prevent such transmission. In areas of low prevalence, vaccination should be limited to those who are in groups identified as being at increased risk or infection.
CONTRAINDICATIONS
Hypersensitivity to yeast or any component of the vaccine.
WARNINGS
Patients who develop symptoms suggestive of hypersensitivity after an injection should not receive further injections of RECOMBIVAX-HB (see CONTRAINDICATIONS).
Because of the long incubation period for hepatitis B, it is possible for unrecognized infection to be present at the time RECOMBIVAX-HB is given. RECOMBIVAX-HB may not prevent hepatitis B in such patients.
PRECAUTIONS

General
As with any percutaneous vaccine, epinephrine should be available for immediate use should an anaphylactoid reaction occur.
Any serious active infection is reason for delaying use of RECOMBIVAX-HB except when, in the opinion of the physician, withholding the vaccine entails a greater risk.
Caution and appropriate care should be exercised in administering RECOMBIVAX-HB to individuals with severely compromised cardiopulmonary status or to others in whom a febrile or systemic reaction could pose a significant risk.
Pregnancy
Pregnancy Category C. Animal reproduction studies nave not been conducted with RECOMBIVAX-HB. It is also not known whether RECOMBIVAX-HB can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. RECOMBIVAX-HB should be given to a pregnant woman only if clearly needed.
Nursing Mothers
It is not known whether RECOMBIVAX-HB is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when RECOMBIVAX-HB is administered to a nursing woman.
Pediatric Use RECOMBIVAX-HB has been shown to be usually well tolerated and highly immuno- RECOMBIVAX-HB is for intramuscular injection. The deltoid muscle is the preferred site for intramuscular injection in adults. Data suggest that injections given in the buttocks Frequently are given into fatty tissue instead of into muscle. Such injections have resulted in a lower seroconversion rate than was expected. The anterolateral thigh is the recommended site for intramuscularTnjection in infants and younqchildren.
RECOMBIVAX-HB"
RECOMBIVAX-HB may be administered subcutaneously to persons at risk of hemorrhage following intramuscular injections. However, when other aluminum-adsorbed vaccines have been administered subcutaneously, an increased incidence of local reactions including subcutaneous nodules has been observed. Therefore, subcutaneous administration should be used only in persons (e.g., hemophiliacs) at risk of hemorrhage following intramuscular injections.
The immunization regimen consists of 3 doses of vaccine. The volume of vaccine to be given on each occasion is as follows: Since there have been no clinical studies in which a vaccine series was initiated with HEPTAVAX-B* (Hepatitis B Vaccine.MSD) and completed with RECOMBIVAX-HB, or vice versa, it is recommended that the 3-dose series be completed with the same vaccine that was used for the initial dose.
Whenever revaccination or administration of a booster dose is appropriate, RECOMBIVAX-HB may be used.
For dosage for infants born of HBsAg positive mothers and for dosage for known or presumed exposure to HBsAg, see the Prescribing Information.
The vaccine should be used as supplied; no dilution or reconstitution is necessary. The full recommended dose of the vaccine should be used. Storage Store vials at 2-8°C (35.6-46.4°FI. Storage above or below the recommended temperature may reduce potency.
Do not freeze since freezing destroys potency. HEPTAVAX-B will not prevent hepatitis caused by other agents, such as hepatitis A virus, non-A, non-B hepatitis viruses, or other viruses known to infect the liver.
Vaccination is recommended in persons of all ages, especially those who are or will be at increased risk of infection with hepatitis B virus.
CONTRAINDICATIONS
Hypersensitivity to any component of the vaccine.
WARNINGS
Persons with immunodeficiency or those receiving immunosuppressive therapy require larger vaccine doses and respond less well than do healthy individuals.
Because of the long incubation period for hepatitis B, it is possible for unrecognized infection to be present at the time HEPTAVAX-B is given. HEPTAVAX-B may not prevent hepatitis B in such patients. Patients who develop symptoms suggestive of hypersensitivity after an injection should not receive further injections of HEPTAVAX-B.
PRECAUTIONS
Genera]
As with any parenteral vaccine, epinephrine should be available for immediate use should an anaphylactoid reaction occur. Any serious active infection is reason for delaying use of this vaccine except when, in the opinion of the physician, withholding the vaccine entails a greater risk. Caution and appropriate care should be exercised in administering this vaccine to individuals with severely compromised cardiopulmonary status or to others in whom a febrile or systemic reaction could pose a significant risk.
Pregnancy
Pregnancy Category C. It is not known whether the vaccine can cause fetal harm when administered to pregnant women or can affect reproductive capacity. The vaccine should be given to a pregnant woman only if clearly needed.
Nursing Mothers
Studies in 12 lactating women have failed to reveal evidence of this vaccine being secreted in breast milk.
Pediatric Use
This vaccine has been shown to be well tolerated and highly immunogenic in infants and children of all ages. Newborns also respond well; maternally transferred antibodies do not interfere with the active immune response to the vaccine. See DOS-AGE AND ADMINISTRATION section in Prescribing Information for recommended pediatric dosage and for recommended dosage for infants born to HBsAg positive mothers. Rash (non-specific) 0.3 In a double-blind, placebo-controlled, clinical trial of 1,330 health-care workers, the frequency of elevations in SGPT (ALT) in vaccine recipients was not significantly different from that in placebo recipients. In marketed use of the vaccine, non-specific abnormalities in SGPT (ALT) and other liver function tests have been reported, but no causal relationship has been established.
ADVERSE REACTIONS
The following additional adverse reactions have been reported with use of the marketed vaccine. Hypersensitivity Reactions Symptoms of immediate hypersensitivity including urticaria, angioedema, and pruritus have "been reported rarely within the first few hours after vaccination. An apparent hypersensitivity syndrome of delayed onset has been reported rarely, days to weeks after vaccination. This has included the following findings: arthritis (usually transient), fever, and dermatologic reactions such as urticaria, erythema multiforme, or ecchymoses. Nervous System Neurological disorders such as: optic neuritis; myelitis, including transverse myelitis; acute radiculoneuropathy including Guillain-Barre syndrome; peripheral neuropathy, including Bell's palsy and herpes zoster. Hematologic I hrombocytopen ia.
HEPTAVAX-B®
IHepatitisB Vaccine, MSD) Special Senses Tinnitus, visual disturbances. Integumentary System Flushing.
DOSAGE AND ADMINISTRATION
Do not inject intravenously or intradermal^.
HEPTAVAX-B is for intramuscular injection. The deltoid muscle is the preferred site for intramuscular injection in adults. Data suggest that injections given in the buttocks frequently are given into fatty tissue instead of into muscle.Such injections may result in a lower seroconversion rate than is expected. The anterolateral thigh is the recommended site for intramuscular injection in infants and children.
HEPTAVAX-B may be administered subcutaneously to persons at risk of hemorrhage following intramuscular injections. The immune responses and clinical reactions following intramuscular and subcutaneous administration of HEPTAVAX-B have been shown to be comparable. However, when other aluminum-adsorbed vaccines have been administered subcutaneously, an increased incidence of local reactions including subcutaneous nodules has been observed. Therefore, subcutaneous administration should be used only in persons (e.g., hemophiliacs) at risk of hemorrhage following intramuscular injections.
Shake well before withdrawal and use. Thorough agitation at the time of administration is necessary to maintain suspension of the vaccine.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.
The immunization regimen consists of 3 doses of vaccine. The volume of vaccine to be given on each occasion is as follows: For dosage for infants born of HBsAg positive mothers and for dosage for known or presumed exposure to HBsAg, see the Prescribing Information.
The vaccine should be used as supplied; no dilution or reconstitution is necessary. The full recommended dose of the vaccine should be used.
Storage
Store vials at 2-8°C (35.6-46.4°F). Storage above or below the recommended temperature may reduce potency Do not freeze since freezing destroys potency. 
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